# Double-blind Study to Evaluate the PK, Efficacy, Safety and Immunogenicity of MB12 Versus Keytruda® in Stage IV NSCLC

> **NCT05668650** · PHASE3 · RECRUITING · sponsor: **Laboratorio Elea Phoenix S.A.** · enrollment: 174 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer Metastatic

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Pembrolizumab biosimilar

## Key facts

- **NCT ID:** NCT05668650
- **Lead sponsor:** Laboratorio Elea Phoenix S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-15
- **Primary completion:** 2024-08
- **Final completion:** 2024-12
- **Target enrollment:** 174 (ESTIMATED)
- **Last updated:** 2024-07-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05668650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05668650, "Double-blind Study to Evaluate the PK, Efficacy, Safety and Immunogenicity of MB12 Versus Keytruda® in Stage IV NSCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05668650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*